Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide-Reference-Cited by-同舟云学术

Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide

Published:2024-05-07 Issue:8 Volume:59 Page:1178-1180
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Sinanidis Ilias,Hochman Michael J.,Tsai Hua-Ling,Randall Michael P.,Bonilla Brandon,Varadhan Ravi,Ambinder Alexander J.^ORCID,Jones Richard J.,DeZern Amy E.^ORCID,Karantanos Theodoros^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02299-y.pdf

Reference12 articles.

1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.

2. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

3. Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6:2847–53.

4. Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1. Available from: https://evidence.nejm.org/doi/10.1056/EVIDoa2200008.

5. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and cellular therapy committee on practice guidelines. Transpl Cell Ther. 2023;29:71–81.